Gemtuzumab Oz Ozogamicin represents a unique step forward in the management of severe myeloblastic leukemia, mainly acute myeloid disease (AML). This novel conjugate combines a engineered antibody specific to the CD33 https://www.targetmol.com/compound/gemtuzumab